Literature DB >> 7439208

Practical and theoretical aspects of phenytoin administration. I. Relationship between dose and plasma concentration.

O Driessen, R J Höppener, E A van der Velde.   

Abstract

In 28 patients the dose-plasma concentration relationship of phenytoin was studied by stepwise varying of the dose of phenytoin and observing the effect on the plasma concentration after an equilibration period of 4 weeks. Plasma concentrations were determined by two laboratories independently. Comedication (only phenobarbital) was fixed. It appeared that after nonconsecutive 4-week equilibration periods, equal doses could yield substantially different plasma concentrations. It is suggested that an equilibration period of at lest 4 weeks must be observed between a dose decrement in the high dose range and a check of the resulting steady state plasma concentration. The slow decrement of phenytoin plasma concentration after decreasing the dose cannot be explained by the Michaelis-Menten concept. In this study the maximum safe dose for never exceeding a phenytoin plasma concentration of 15 microgram/ml ws 200 mg/24 h. For phenobarbital a ratio of about 1:10 or more between dose (in mg/kg/24 h) and plasma concentration (in microgram/ml) was nearly always observed in 27 of 28 patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439208     DOI: 10.1159/000115175

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  3 in total

Review 1.  Erythrocytes and the transport of drugs and endogenous compounds.

Authors:  M S Highley; E A De Bruijn
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Prediction of phenytoin dosage in relation to the variability of phenytoin plasma concentration.

Authors:  E A Van der Velde; O Driessen
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

Review 3.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.